MedTrace Logo

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

NCT00957437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-11-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics of different extended-release formulations of AZD1305 when given as single and multiple oral doses to healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

AZD1305

Single Oral Dose, ER formulation 1

DRUG

AZD1305

ER formulation 1, bid for 5 days

DRUG

AZD1305

Single Oral Dose, ER formulation 2

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde · AstraZeneca R&D, Mölndal, Sweden

  • Klaus Francke · PAREXEL Early Phase Clinical Unit, London UK.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Completion
2009-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957437 on ClinicalTrials.gov